Ad
related to: alk lymphoma kinase 2 deficiency causes depression and cancer disease in men
Search results
Results From The WOW.Com Content Network
Anaplastic lymphoma kinase (ALK) was originally discovered in 1994 [5] [7] in anaplastic large-cell lymphoma (ALCL) cells. ALCL is caused by a (2;5)(p23:q35) chromosomal translocation that generates the fusion protein NPM-ALK, in which the kinase domain of ALK is fused to the amino-terminal part of the nucleophosmin (NPM) protein.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
ALK, i.e. anaplastic lymphoma kinase, is a protein product of the ALK gene located on chromosome 2. In ALK-positive ALCL, a portion of the ALK gene has merged with another site on the same or different chromosome to form a chimeric gene consisting of part of the new site and part of the ALK gene coding for ALK's activity. [4]
ALK+ large B-cell lymphoma is a type of lymphoma. [ 1 ] [ 2 ] : 378 It was first reported in 1997. [ 2 ] : 378 [ 3 ] [ 4 ] It is a rare, aggressive large B-cell process that shows ALK expression.
About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion gene between EML4 ('echinoderm microtubule-associated protein-like 4') and ALK ('anaplastic lymphoma kinase'), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant ...
Major depression is often associated with biomarkers indicative of inflammatory responses, with interleukin-6, interleukin-1, interleukin-2 receptor, tumor necrosis factor alpha, C-reactive protein, and monocyte chemotactic protein-1 all being found to be elevated in those with depression. [2] [8] [1] [5] [3] Similarly, the same biomarkers are ...
Bruton tyrosine kinase inhibitors , such as such as ibrutinib, zanubrutinib, and acalabrutinib; B-cell lymphoma-2 inhibitor, venetoclax, plus a CD20 antibody obinutuzumab, OR; BTKi (i.e. ibrutinib) plus BCL-2 inhibitor (i.e. venetoclax) [15] [16] [17] CLL is the most common type of leukemia in the Western world.
Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. [8] [9] Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.